U014 - Controversies in Calciphylaxis: An Overview of Pathogenesis, Diagnosis, and Treatment through Case Studies
Friday, February 16; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Identify risk factors for developing uremic and non-uremic calciphylaxis.
- Describe cutaneous manifestations of calciphylaxis and recognize the utility of various histologic features in making the diagnosis.
- Discuss the differential diagnosis of calciphylaxis, as well as challenges in rendering the correct diagnosis, and formulate multidisciplinary treatment strategies.
Calciphylaxis, or calcific uremic arteriolopathy, is considered a rare disease with poor prognosis. It is characterized by vascular calcification with accompanying intimal hypertrophy and small vessel thrombosis, resulting in skin ulceration and necrosis. Calciphylaxis may be more common than previously recognized with an increasing number of individuals, with and without end stage renal disease, being diagnosed with this disorder. This session will use an audience-response and case-based format to review current knowledge surrounding the pathophysiology, risk factors, clinical and diagnostic features, and management options for this challenging disease.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Fernandez, Anthony, MD: AbbVie – C(H), I(H), SP(H); Celgene Corporation – SP(H); Mallinckrodt Pharmaceuticals – I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding);
- Warren, Christine Baran, MD, MS: UpToDate, Inc. – O(NC);